99mTc-MIP-1404 SPECT/CT for Patients With Metastatic Prostate Cancer: Interobserver and Intraobserver Variability in Treatment-Related Longitudinal Tracer Uptake Assessments of Prostate-Specific Membrane Antigen–Positive Lesions. (February 2020)

• Record Type: Journal Article
• Authors: Schmidkonz, Christian; Atzinger, Armin; Goetz, Theresa Ida; Beck, Michael; Ritt, Philipp; Prante, Olaf; Kuwert, Torsten; Bäuerle, Tobias; Cordes, Michael
• Is Part Of: Clinical nuclear medicine. Volume 45:Number 2(2020)
• Publication Date: 2020-02
• Subjects: 99mTc-MIP-1404 -- absolute quantification -- prostate cancer -- PSMA -- sequential SPECT/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002880
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Background: 99m Tc-MIP-1404 is a SPECT-suitable prostate-specific membrane antigen (PSMA) ligand for detection of prostate cancer. In patients with metastatic prostate cancer, there are no data as yet on interobserver and intraobserver variability when assessing PSMA-positive lesions for longitudinal changes of tracer uptake. Methods: 99m Tc-MIP-1404 SPECT/CT scans of 22 patients with metastatic prostate cancer were analyzed, and each subject was imaged at 2 separate points in time, before and after treatment. Mean interval between scans was 10 months. Three independent observers visually assessed a total of 96 PSMA-positive metastases (bone, 69; lymph node, 22; viscera, 3) or local recurrences (n = 2) for longitudinal changes in tracer uptake on planar scintigraphy and SPECT/CT. All lesions were categorized as regressive, stable, or progressive based on visual findings and on peak SUV (SUVpeak) of quantitative SPECT/CT (progressive, >30% SUVpeak increase; regressive, <30% SUVpeak decrease; or stable, all others). Results: Quantitative analysis of PSMA-positive lesions yielded significantly higher interobserver agreement (90.6%; 95% confidence interval [CI], 0.83%–0.96%) than visual assessments by either SPECT/CT (76.0%; 95% CI, 0.66%–0.84%) or planar scintigraphy (56.3%; 95% CI, 0.46%–0.66%). Intermethod comparison of aggregated results yielded significantly higher agreement between quantitative and visual SPECT/CT (85.1%; 95% CI, 0.80%–0.89%), as opposed to quantitative SPECT/CT and planar scintigraphy (53.1%; 95% CI, 0.47%–0.59%) or visual SPECT/CT and planar scintigraphy (54.9%; 95% CI, 0.49%–0.61%). In visual and quantitative analysis of 96 PSMA-positive lesions, the number of discrepancies ranged from 9 (9.4%) for quantitative SPECT/CT to 42 (43.8%) for planar scintigraphy. Overall reader confidence was higher for SPECT/CT than for planar scintigraphy ( P < 0.001). Intraobserver agreement was near-perfect for all methods, whether SPECT/CT (visual, all κ = 0.94–0.97; quantitative κ = 0.94–0.98) or planar scintigraphy (all κ = 0.90–0.94). Conclusions: Quantitative evaluation of longitudinal change in tracer uptake by PSMA-positive lesions measured via SPECT/CT is superior to visual interpretation of images by planar scintigraphy or SPECT/CT. Compared with visual evaluation, quantitative SPECT/CT is highly reproducible, showing near-perfect agreement among observers and higher reader confidence.